Percutaneous coronary intervention (PCI) with dual-antiplatelet therapy (DAPT, aspirin and P2Y12 inhibitor or thienopyridine) is a standardized treatment for coronary artery disease (CAD) patients with moderate or severe coronary artery stenosis, 5% to 15% of whom are concomitant atrial fibrillation (AF)[1–3]. This evidence concerns the gene P2RY12 and atrial fibrillation.